Four local research teams have been awarded nearly $75 million in funding from the California Institute of Regenerative Medicine for projects to develop drugs for leukemia, Lou Gehrig's disease and brain tumors.
The local grants include:
$20 million to a team led by Dennis A. Carson, M.D., director of the Moores UCSD Cancer Center and professor of medicine, and Catriona Jamieson, M.D., Ph.D., assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores center. Their team will work to develop novel drugs against leukemia stem cells, collaborating with a Canadian research team.
$10.8 million to a Salk Institute team focusing on developing a novel stem cell-based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's disease.
$19.2 million to a team led by Mitchel Berger of UC San Francisco with co-principal investigator Webster Cavenee, a professor at UCSD School of Medicine and the Ludwig Institute for Cancer Research at UCSD. It also includes Evan Snyder, M.D., Ph.D., director and professor of the Burnham Institute's Stem Cells and Regenerative Biology program. They will work to find a treatment for brain tumors using neural stem cells that have been genetically modified to carry a tumor-killing drug.
$20 million to Novocell, which will work with a team from UC San Francisco headed by Dr. Jeff Bluestone for work on a cellular therapy for the treatment of diabetes.
Although the Del Mar Times does not have any obligation to monitor this board, the Del Mar Times reserves the right at all times to check this board and to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable to the Del Mar Times in our sole discretion and to disclose any information necessary to satisfy the law, regulation, or government request. The Del Mar Times also reserves the right to permanently block any user who violates these terms and conditions. All threats to systems or site infrastructure shall be assumed genuine in nature and will be reported to the appropriate law enforcement authorities. Submission of any comments will be considered permission to use online or in print.
